Luteinizing Hormone Veterinary Grade API, also designated interstitial cell-stimulating hormone, is a dimeric glycoprotein supplied as a sterile-filtered, lyophilised powder for direct formulation into tablets, injections, capsules, powders, granules, premix, and solutions. The manufacturing stream uses sequential ion-exchange chromatography and hydrophobic interaction chromatography from controlled animal-origin pituitary glands or from mammalian cell expression, followed by viral inactivation at low pH and nanofiltration. Product model suffixes LH-VET-API-1000, LH-VET-API-5000, and LH-VET-API-10000 denote nominal International Units per vial after reconstitution in 0.9% sodium chloride or phosphate-buffered saline. Actual biological activity is measured against a species-appropriate reference preparation by receptor-binding assay or ovarian ascorbic acid depletion, and the powder is white to off-white with residual moisture ≤3.0% as determined by Ph. Eur. 2.5.12. The compound is used for ovulation induction, estrus synchronisation, superovulation before embryo transfer, and male fertility management in cattle, sheep, goats, camelids, and equine medicine. Release for a given formulation must state the target species because receptor-binding affinity and glycosylation differ among mammalian species.

Which Pharmacopoeial and VICH Requirements Define the Injectable-Grade Release Criteria?

Injectable-grade LH-VET API is released against a specification that combines physical identity, in vivo potency, purity, and microbial safety controls. Batch release data are generated with pharmacopoeial general methods and supporting ISO 9001:2015 quality-system documentation. Endotoxin control follows Ph. Eur. 2.6.14, sterility for terminally sterilised or aseptically processed presentations follows Ph. Eur. 2.6.1, and residual solvent acceptance follows VICH GL18 class 3 limits. The table below summarises representative release parameters for the injectable-grade powder.

Endotoxin limits for oral powders, premix carriers, and capsule diluents can be wider than the injectable criterion, but bioburden control remains critical when the API is later sterile-filtered. The lyophilised powder is hygroscopic; opening under ambient relative humidity above 60% requires pre-drying of excipients and controlling room dew point to avoid moisture-induced aggregation and loss of monomer content during storage.

Glycosylation defines the biological fate of the API. The luteinizing hormone beta subunit carries one N-linked oligosaccharide and additional O-linked glycans with terminal sulfate or sialic acid residues in some species. This microheterogeneity influences receptor residence time, hepatic clearance, and batch-to-batch potency variance. Consequently, release documentation includes an isoform profile by isoelectric focusing or capillary electrophoresis, with the principal band distribution typically observed between pI 6.0 and 8.0. Molecular mass of the intact heterodimer ranges from approximately 28 kDa to 38 kDa depending on source species and glycan occupancy. These attributes are not cosmetic; they determine whether a given batch can be substituted into an injectable ovulation protocol without altering superovulatory response.

Solid-Dose Blending and Compression Limits for LH-VET-API Granules

For tablets, capsules, powders, and granules, the API is commonly supplied as a micronised or spray-dried grade with a volume median particle diameter of ≤25 µm as determined by laser diffraction. Low-dose blending requires geometric dilution through a 600 µm screen followed by extended tumble blending in a V-blender or bin blender. High-shear granulation is not recommended for open protein API because the local heat input can exceed 40 °C at impeller tip speeds above 5 m/s, producing insoluble aggregates. If aqueous granulation is unavoidable, fluid-bed inlet air temperature should be maintained below 40 °C and product temperature below 30 °C. Direct compression tablets are feasible when the API is dry-blended with microcrystalline cellulose and crospovidone, but compression force should remain between 8 kN and 14 kN on a rotary tablet press. Below 8 kN, hardness can fall below 30 N and result in friability above 1.0%; above 14 kN, protein denaturation at the tablet surface may reduce in vitro potency recovery when the tablet is reconstituted or dispersed.

Batch-to-batch variance in particle-size distribution and moisture content is the main processing bottleneck on production-scale tablet lines. When the API is dried below 2.0% moisture, the lyophilised cake becomes brittle and produces excessive fines during sieving, leading to segregation in the feed frame. When moisture exceeds 4.0%, stickiness can occur during compression. Therefore, controlled packaging in aluminium foil with silica gel desiccant and storage at 2–8 °C is specified. For premix applications, the API is adsorbed onto lactose monohydrate or maltodextrin carrier with a target active concentration from 1 IU/g to 10 000 IU/g, depending on the final medicated feed inclusion rate. Homogeneity is verified by taking 10 sampling points across a ribbon blender or conical screw mixer; relative standard deviation of the assay must not exceed 5% for regulatory batch release.

If the Target Formulation Is a Sterile Injectable, What Reconstitution and Filtration Parameters Are Critical?

Injectable solutions are compounded by adding the lyophilised LH-VET API to phosphate-buffered saline or 0.9% sodium chloride at 2–8 °C. Final protein concentration should be maintained between 0.1 mg/mL and 5 mg/mL unless a stabiliser is present. Agitation should be limited to gentle swirling because vortex mixing introduces air-liquid interface stress and accelerates dimer dissociation and aggregation. Filtration through low-protein-binding polyethersulfone membranes with a pore size of 0.22 µm is preferred; nylon membranes can bind the glycoprotein and reduce filterable recovery by up to 15% in low-ionic-strength buffers. The filtered solution must be used within 24 h when stored at 2–8 °C and should not be refrozen because repeated freeze-thaw cycles reduce receptor-binding activity.

Terminal sterilisation by autoclave is generally incompatible with the intact heterodimer. Steam sterilisation at 121 °C for 15 min produces deamidation and subunit dissociation, with potency loss commonly above 30%. Aseptic processing is therefore the standard route for injectable veterinary LH products. If preservative-containing multi-dose vials are required, benzyl alcohol at 0.9% v/v may be used; however, the formulator must confirm compatibility in the target species because benzyl alcohol is restricted in certain neonatal and feline applications. The final injectable should be clear to slightly opalescent after reconstitution and must meet Ph. Eur. 2.9.20 particulate matter limits for small-volume parenterals.

Species-specific potency conversion remains an operational boundary. A batch standardised in a rat or bovine receptor model may not predict the equine or camelid response because of differences in luteinizing hormone receptor glycosylation and circulating clearance. Published multi-species potency data for this specific configuration is limited, so target-species bioassay verification is required before changing API source or manufacturing site.

Comparative Potency, Glycosylation, and Receptor Residence Time Against hCG and Menotropins

The main differentiating feature of veterinary LH API compared with human chorionic gonadotropin, menotropins, and pituitary follicle-stimulating hormone preparations is receptor specificity combined with shorter plasma residence time. Human chorionic gonadotropin binds the same luteinizing hormone receptor but carries a C-terminal peptide extension with O-linked glycans that prolongs circulating half-life and increases receptor dwell time. Veterinary pituitary LH lacks that extension, producing a more transient luteotrophic signal. This is relevant when repeated ovulation induction is performed in embryo transfer programmes, because prolonged receptor occupancy by human chorionic gonadotropin can desensitise luteal cells and alter subsequent cycle response.

For oral or premix presentations, the protein nature of the API imposes an additional constraint not shared by synthetic small-molecule reproductive aids. Gastrointestinal degradation of the intact glycoprotein reduces systemic bioavailability unless enteric protection or mucosal delivery is designed. Therefore, tablets and capsules intended for oral use in veterinary species are generally formulated as enteric-coated or targeted-release systems; immediate-release oral powders may be suitable only for local or diagnostic applications where systemic absorption is not required. This is a fundamental difference from synthetic prostaglandin analogue tablets or altrenogest oral solutions, which are absorbed systemically without the same degradation issue.

Granule and premix formulations for feed or drench use should be tested for potency recovery after 30 min and 60 min in simulated gastric fluid at pH 1.2 and simulated intestinal fluid at pH 6.8. Formulators are advised to avoid combinations with amine-based pellet binders or strongly acidic carrier acids because low pH-induced subunit dissociation can occur within minutes. The API should also not be dry-blended with reducing sugars such as lactose in heated processes above 40 °C unless stabilisation has been validated, because Maillard-type conjugation can alter glycan residues and reduce receptor binding.

Storage of the finished veterinary medicinal product should follow the same cold-chain requirements as the API: protected from light, maintained at 2–8 °C for injectable and solution forms, and at controlled room temperature below 25 °C only when a stability study has demonstrated label claim retention for the assigned shelf life. The lyophilised API is incompatible with strong oxidising agents and should not be exposed to ethylene oxide sterilisation unless residual ethylene oxide and ethylene chlorohydrin limits are met under 21 CFR 211 batch release criteria. For all formulation types, the batch record must include a reconciliation of International Units from API input to finished product output, because potency loss during compression, drying, or sterile filtration is not uniformly linear across species.